Korean drug maker Celltrion Healthcare recently presented new findings from a 2-part study at the European League Against Rheumatism European Congress of Rheumatology 2019 meeting about subcutaneous biosimilar CT-P13 (Inflectra, Remsima).
Korean drug maker Celltrion Healthcare recently presented new findings from a 2-part study at the European League Against Rheumatism European Congress of Rheumatology 2019 meeting about subcutaneous biosimilar CT-P13 (Inflectra, Remsima).
The company said subcutaneous CT-P13 may enhance treatment options for the use of biosimilar infliximab by providing high consistency in drug exposure and a convenient method of administration.
The proposed subcutaneous formulation of CT-P13 is currently under European Medicines Agency evaluation. The proposed formulation of the drug will also be studied in the United States in a phase 3 program in patients with inflammatory bowel disease.
The first part of the study investigated the pharmacokinetics, efficacy, and overall safety of CT-P13 in patients with rheumatoid arthritis during a treatment period of 1 year, as compared with the intravenous (IV) formulation of CT-P13. After enrolling 50 patients, 48 patients were randomly assigned at week 6 into 4 cohorts in a 1:1:1:1 ratio. The IV cohort received CT-P13 IV 3mg/kg every 8 weeks and the SC cohorts received CT-P13 SC 90mg, 120mg or 180mg, respectively, every 2 weeks up to week 54.
Overall, the efficacy and safety results of subcutaneous CT-P13 up to week 54 were comparable to those of the IV formulation. Disease improvement was assessed using 2 disease scores for RA, the disease activity score in a count of 28 joints with C-reactive protein (DAS28-CRP) and the American College of Rheumatology criteria for 20% improvement (ACR20) score. Results demonstrated that DAS28-CRP and ACR20 were comparable across all 4 cohorts, regardless of the route of administration or dosage of CT-P13. The safety profiles at week 6 in subcutaneous CT-P13 were comparable to CT-P13 IV and were similar to those previously reported for IV infliximab.
In the second part of the study, subcutaneous CT-P13 was shown to be noninferior in terms of efficacy and compared safety profiles compared with CT-P13 IV in people with RA over 30 weeks.
This study was followed by a phase 1/3 randomised controlled trial. A total of 362 RA patients were enrolled, of whom 348 were randomized at week 6 into 2 treatment arms in a 1:1 ratio (169 and 179 patients in SC 120mg biweekly or IV 3mg/kg arms every 8 weeks, respectively).
The trial showed that the mean change of DAS28-CRP from baseline to week 22 was similar between the 2 arms. The lower limit of the 95% CI (0.03) for the treatment difference in the change of DAS28-CRP from baseline was greater than the prespecified noninferiority margin (—0.6) indicating non-inferiority of CT-P13 SC compared to CT-P13 IV.
ACR20 responses were also similar between the 2 treatment arms up to week 22, and the safety profiles at week 6 were also comparable.
Cost and Efficacy Insights on Infliximab Biosimilars in Pediatric Uveitis
December 3rd 2024The study highlights the safety, efficacy, and cost benefits of infliximab biosimilars in managing pediatric noninfectious uveitis, showing fewer disease flares and reduced costs compared with reference infliximab, as well as the influence of insurance mandates on treatment decisions.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.